Clinical evaluation of youth with pediatric acute-onset neuropsychiatric syndrome (PANS): recommendations from the 2013 PANS Consensus Conference.
Kiki Chang, Jennifer Frankovich, Michael Cooperstock...
https://pubmed.ncbi.nlm.nih.gov/25325534/Actively Recruiting
Led by Stanford University · Updated on 2016-10-06
500
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are investigating Pediatric Acute-Onset Neuropsychiatric Syndrome PANS, a condition in children characterized by a sudden onset of obsessive-compulsive disorder or eating restrictions along with severe neuropsychiatric symptoms such as anxiety, depression, irritability, and behavioral changes. The study aims to explore neurologic, immunologic, rheumatologic, and genomic markers to better understand the underlying autoimmune processes involved in childhood psychiatric disorders. This research seeks to uncover causes that might lead to better-targeted treatments in the future. The study will recruit 500 children aged 1 to 18 years who are newly diagnosed with PANS or PANDAS and have not yet received treatment, along with 100 healthy children matched by age and gender for comparison. The participants will be evaluated for differences in immunologic, neurologic, genomic, and behavioral factors between the two groups. This observational study will follow children through onset or exacerbation of symptoms and compare findings with healthy controls. Participants will undergo regular assessments including cerebral blood flow measurements, EEG patterns, and REM motor disinhibition evaluations for up to 12 years. Every 2 to 4 weeks, global impairment scores, obsessive-compulsive symptom scales, caregiver burden inventories, neurological findings, and other behavioral assessments will be collected. These extensive evaluations are intended to monitor the progression and characteristics of PANS and to identify key markers associated with the disorder over time.
CONDITIONS
Neurobiologic, Immunologic, and Rheumatologic Markers in Youth With PANS
J
Joanne Cheung
E
Ellen Spartz
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Stanford University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 12 years
Participants are monitored over time to assess neurobiologic, immunologic, and rheumatologic markers, as well as behavioral and neurological outcomes.
Visits every 2 to 4 weeks for assessments
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Kiki Chang, Jennifer Frankovich, Michael Cooperstock...
https://pubmed.ncbi.nlm.nih.gov/25325534/Tanya K Murphy, Diana M Gerardi, James F Leckman
https://pubmed.ncbi.nlm.nih.gov/25150567/Stanford University
Lead Sponsor